Literature DB >> 30690054

Cathepsin-sensitive nanoscale drug delivery systems for cancer therapy and other diseases.

Divya Dheer1, Julien Nicolas2, Ravi Shankar3.   

Abstract

Cathepsins are an important category of enzymes that have attracted great attention for the delivery of drugs to improve the therapeutic outcome of a broad range of nanoscale drug delivery systems. These proteases can be utilized for instance through actuation of polymer-drug conjugates (e.g., triggering the drug release) to bypass limitations of many drug candidates. A substantial amount of work has been witnessed in the design and the evaluation of Cathepsin-sensitive drug delivery systems, especially based on the tetra-peptide sequence (Gly-Phe-Leu-Gly, GFLG) which has been extensively used as a spacer that can be cleaved in the presence of Cathepsin B. This Review Article will give an in-depth overview of the design and the biological evaluation of Cathepsin-sensitive drug delivery systems and their application in different pathologies including cancer before discussing Cathepsin B-cleavable prodrugs under clinical trials.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Cathepsins; Drug delivery; Enzymes; Optical imaging

Mesh:

Substances:

Year:  2019        PMID: 30690054     DOI: 10.1016/j.addr.2019.01.010

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  12 in total

Review 1.  Built to last: lysosome remodeling and repair in health and disease.

Authors:  Roberto Zoncu; Rushika M Perera
Journal:  Trends Cell Biol       Date:  2022-02-02       Impact factor: 21.167

2.  29th Annual GP2A Medicinal Chemistry Conference.

Authors:  Jean-Jacques Helesbeux; Laura Carro; Florence O McCarthy; Vânia M Moreira; Francesca Giuntini; Niamh O'Boyle; Susan E Matthews; Gülşah Bayraktar; Samuel Bertrand; Christophe Rochais; Pascal Marchand
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-07

Review 3.  Coumarin as a structural component of substrates and probes for serine and cysteine proteases.

Authors:  Julian Breidenbach; Ulrike Bartz; Michael Gütschow
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2020-05-13       Impact factor: 3.036

4.  Current Status and Perspectives of Protease Inhibitors and Their Combination with Nanosized Drug Delivery Systems for Targeted Cancer Therapy.

Authors:  Magdalena Rudzińska; Cenk Daglioglu; Lyudmila V Savvateeva; Fatma Necmiye Kaci; Rodolphe Antoine; Andrey A Zamyatnin
Journal:  Drug Des Devel Ther       Date:  2021-01-06       Impact factor: 4.162

Review 5.  Harnessing Endogenous Stimuli for Responsive Materials in Theranostics.

Authors:  Alexander B Cook; Paolo Decuzzi
Journal:  ACS Nano       Date:  2021-02-08       Impact factor: 15.881

6.  Dendrimer-Like Supramolecular Assembly of Proteins with a Tunable Size and Valency Through Stepwise Iterative Growth.

Authors:  Jin-Ho Bae; Hong-Sik Kim; Gijeong Kim; Ji-Joon Song; Hak-Sung Kim
Journal:  Adv Sci (Weinh)       Date:  2021-10-31       Impact factor: 16.806

Review 7.  Targeting lysosomes in human disease: from basic research to clinical applications.

Authors:  Mengdie Cao; Xiangyuan Luo; Kongming Wu; Xingxing He
Journal:  Signal Transduct Target Ther       Date:  2021-11-08

Review 8.  Designing bioresponsive nanomaterials for intracellular self-assembly.

Authors:  Sarah Chagri; David Y W Ng; Tanja Weil
Journal:  Nat Rev Chem       Date:  2022-04-01       Impact factor: 34.571

9.  Doxorobicin as cargo in a redox-responsive drug delivery system capped with water dispersible ZnS nanoparticles.

Authors:  Lukáš Žid; Vladimír Zeleňák; Vladimír Girman; Jozef Bednarčík; Adriana Zeleňáková; Jaroslava Szűcsová; Virginie Hornebecq; Alexander Hudák; Monika Šuleková; Lucia Váhovská
Journal:  RSC Adv       Date:  2020-04-21       Impact factor: 4.036

Review 10.  Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency.

Authors:  Zhilin Li; Xiaoqin Lai; Shiqin Fu; Long Ren; Hao Cai; Hu Zhang; Zhongwei Gu; Xuelei Ma; Kui Luo
Journal:  Adv Sci (Weinh)       Date:  2022-06-02       Impact factor: 17.521

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.